Fig. 1.
Fig. 1. RT-PCR amplification products of the indicated genes obtained with bone marrow samples from 8 different patients with MGUS (no. 5), myeloma stage I (no. 12), or myeloma stage III (nos. 21 through 39). C+, positive control melanoma line (MZ2-MEL for MAGE-A3, GAGE-3/6, and β-ACTIN; LB373-MEL for LAGE-1 and PRAME). C−, negative control (no RNA present in the RT reaction). MW, molecular weight marker is SmartLadder (Eurogentec, Seraing, Belgium). Amplifications of MAGE-A3, GAGE-3/6, PRAME, and β-ACTIN transcripts give unique bands of 725, 244, 561, and 615 bp, respectively. Amplification of LAGE-1 transcript gives 2 bands that correspond to fully spliced (399 bp) and partially spliced (628 bp) mRNA, respectively, and a band of approximately 600 bp representing heteroduplexes formed during PCR between the products amplified from the partially and the fully spliced cDNAs.

RT-PCR amplification products of the indicated genes obtained with bone marrow samples from 8 different patients with MGUS (no. 5), myeloma stage I (no. 12), or myeloma stage III (nos. 21 through 39). C+, positive control melanoma line (MZ2-MEL for MAGE-A3, GAGE-3/6, and β-ACTIN; LB373-MEL for LAGE-1 and PRAME). C−, negative control (no RNA present in the RT reaction). MW, molecular weight marker is SmartLadder (Eurogentec, Seraing, Belgium). Amplifications of MAGE-A3, GAGE-3/6, PRAME, and β-ACTIN transcripts give unique bands of 725, 244, 561, and 615 bp, respectively. Amplification of LAGE-1 transcript gives 2 bands that correspond to fully spliced (399 bp) and partially spliced (628 bp) mRNA, respectively, and a band of approximately 600 bp representing heteroduplexes formed during PCR between the products amplified from the partially and the fully spliced cDNAs.

Close Modal

or Create an Account

Close Modal
Close Modal